Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

Background: It is unknown if, after controlling for clinicopathologic variables and treatment, racial disparities in colon cancer outcomes persist. Molecular marker analysis in North American patients comparing Asians with other races has not been reported. Methods: BRAF V600E and KRAS mutations were analyzed in node-positive colon cancer patients (n = 3305) treated with FOLFOX-based chemotherapy in an adjuvant trial (Alliance N0147). Race categories included Asian, black, or white. Cox models were used to estimate disease-free survival (DFS) and time to recurrence (TTR). All statistical tests were two-sided. Results: BRAF mutation frequency in tumors from whites (13.9%) was twice that of tumors from Asians or blacks. KRAS mutation rates were highest in tumors from blacks (44.1%). KRAS/BRAF wild-type tumors were most common among Asians (66.7%) (P overall interaction

Original languageEnglish (US)
Article numberdjv186
JournalJournal of the National Cancer Institute
Volume107
Issue number10
DOIs
StatePublished - Oct 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this